Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib plus capecitabine in chemotherapy-resistant colorectal cancer with peritoneal metastases
NL-OMON58949Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of galunisertib and capecitabine in colorectal cancer (CRC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and recommended phase 2 dose and Objective response rate. Started Jul 2023; status: completed.
02
Drugs
galunisertibcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON58949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58949.